Back to News
Market Impact: 0.3
Novo partners with Anthropic to speed up drug development with Claude
Source: reuters.com
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
Novo Nordisk partnered with Anthropic to deploy Claude AI models in accelerating the discovery and development of new medicines. The collaboration could improve R&D productivity and reinforce Novo Nordisk's use of AI in drug development, though no financial terms or timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NVO0.55
More News
- Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030
- Companies promised AI gains— here's how the payoff showed up in earnings
- AWS grows 39% and Amazon will spend even more on AI in 2027
- Stocks started the week with promise but ended in despair. Our take on the big reversal
- Fears over $828 billion AI capex spending spree help erase $1 trillion in market value
- Intel stock plunges 29%. Analysts urge caution on buying the dip